Santhera Updates Development Strategy for SNT-MC17/idebenone in Friedreich's Ataxia in the US
Revised Clinical and Regulatory Strategy Based on Discussions with FDA Potentially Allows for Accelerated Development Timelines
Santhera Pharmaceuticals announced a revised clinical and regulatory strategy aimed at accelerating the development timelines for its lead compound SNT-MC17/idebenone in Friedreich's ataxia (FRDA) in the US. These changes are the result of discussions with the FDA (US food and Drug Administration) following the positive results of the Company's collaborative clinical trial with the US National Institutes of Health (NIH).
It is anticipated that both the number of patients needed for the Phase III clinical study and the trial's duration could be significantly reduced, thereby shortening the development timelines approximately by half a year as compared to the Company's previous plans. The positive results of the clinical study conducted in collaboration with the NIH were presented at the 3rd International Friedreich's Ataxia Scientific Conference in Bethesda, Maryland. Specifically, this trial showed improvement of neurological parameters and activities of daily living scores with intermediate and high doses of SNT-MC17/idebenone after six months of treatment in young FRDA patients.
Santhera submitted these data to the FDA in late 2006. In a recent meeting with the Agency, the Company discussed potential amendments to its US clinical development plans for SNT-MC17/idebenone based on these new data. As a result of this meeting, Santhera will file a new protocol under its open IND (Investigational New Drug) within the next few weeks.
According to this protocol, the number of patients involved in the pending Phase III trial will be reduced substantially while the treatment period with SNT-MC17/idebenone will be considerably shortened. The protocol will reflect the major findings from the collaborative clinical trial with the NIH regarding neurological endpoints and the efficacy seen with the intermediate and high dose of SNT-MC17/idebenone. Upon filing the new protocol, Santhera will ask, as recommended by the FDA, for Special Protocol Assessment (SPA) with the Agency which is expected to occur within the next three months. Based on this schedule of events, patient recruitment is expected to start in summer 2007.
Other news from the department research and development
